<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04867525</url>
  </required_header>
  <id_info>
    <org_study_id>IOM-100452</org_study_id>
    <nct_id>NCT04867525</nct_id>
  </id_info>
  <brief_title>Registry Platform Colorectal Cancer</brief_title>
  <acronym>AZURITE</acronym>
  <official_title>Clinical Research Platform for Molecular Testing, Treatment, Quality of Life and Outcome of Patients With Metastatic Colorectal Cancer Receiving Systemic Therapy (AZURITE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The registry aims to collect and analyse information on the antineoplastic treatment of&#xD;
      patients with metastatic colorectal cancer, treated in palliative intention in daily routine&#xD;
      practice in Germany.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AZURITE is a national, observational, prospective, longitudinal, multicenter cohort study&#xD;
      (tumor registry platform) with the purpose to record information on the antineoplastic&#xD;
      treatment of metastatic colorectal cancer in Germany. The registry will follow patients for&#xD;
      up to three years. It will identify common therapeutic sequences and changes in the treatment&#xD;
      of the disease. At inclusion, data in patient characteristics, comorbidities, tumor&#xD;
      characteristics and previous treatments are collected. During the course of observation data&#xD;
      on all systemic treatments, radiotherapies, surgeries, and outcome are documented.&#xD;
&#xD;
      Health-related quality of life (HRQoL) will be evaluated for up to three years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">May 2026</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Course of treatment (treatment reality).</measure>
    <time_frame>3 years per patient.</time_frame>
    <description>Documentation of anamnestic data and therapy sequences.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Response.</measure>
    <time_frame>3 years per patient.</time_frame>
    <description>Documentation of response rates per line of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival.</measure>
    <time_frame>3 years per patient.</time_frame>
    <description>Documentation of progression-free survival per line of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival.</measure>
    <time_frame>3 years per patient.</time_frame>
    <description>Documentation of overall survival per line of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (Patient-reported outcome, PRO).</measure>
    <time_frame>3 years per patient.</time_frame>
    <description>EORTC QLQ-C30 core questionnaire [European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; Scale 0-100; a high scale score represents a higher response level: (a) global health status: a high score represents high quality of life, (b) functional scales: a high score represents high/healthy level of functioning, (c) symptom scales/items: a high score represents high level of symptomatology or problems].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carcinoma Health-related quality of life (Patient-reported outcome, PRO).</measure>
    <time_frame>3 years per patient.</time_frame>
    <description>EORTC QLQ-CR29 [European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; Scale 0-100; a high score for scales and single items represents a high level of symptomatology or problems].</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Colorectal Cancer Metastatic</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physician's choice according to patient's needs.</intervention_name>
    <description>Routine care as per site standard.</description>
    <arm_group_label>Colorectal Cancer Metastatic</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with metastatic (stage IV) colorectal cancer requiring palliative systemic&#xD;
        first-line therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically proven metastatic colorectal cancer (stage IV) at time of&#xD;
             inclusion (patients with metastatic disease and potential curative treatment intention&#xD;
             are allowed)&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Planned first systemic therapy for metastatic disease&#xD;
&#xD;
          -  Signed and dated informed consent form&#xD;
&#xD;
               -  Patients participating in the PRO module: prior to or at start of first systemic&#xD;
                  treatment for mCRC&#xD;
&#xD;
               -  Patients not participating in the PRO module: within four weeks after start of&#xD;
                  fist systemic therapy for mCRC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who do not receive any systemic therapy for mCRC&#xD;
&#xD;
          -  Patients whose metastatic disease was surgically resected prior to inclusion and who&#xD;
             start adjuvant chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Graf, PD Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Deggendorf</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank Kullmann, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Weiden i.d.O.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Marschner</last_name>
    <role>Study Chair</role>
    <affiliation>Freiburg i.Br.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marlies Michl, PD Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>München</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens Neumann, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>München</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roland Schnell, PD Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Frechen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sebastian Stintzing, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Berlin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>iOMEDICO AG</last_name>
    <phone>+49 761 15242-0</phone>
    <email>info@iomedico.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Multiple sites all over germany</name>
      <address>
        <city>Multiple Locations</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>iOMEDICO AG</last_name>
      <phone>+49 761 152420</phone>
      <email>info@iomedico.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

